PR
PRPH.US ProPhase Labs Inc
- Market cap
- USD 90.4K
- P/E
- -
- P/B
- 0.37x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is PRPH.US undervalued?
Graham numberThe Graham number of ProPhase Labs Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ProPhase Labs Inc fundamental analysis
No fundamental analysis for ProPhase Labs Inc yet.
ProPhase Labs Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ProPhase Labs Inc
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophage…
Full company profileProPhase Labs Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ProPhase Labs Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 21.0M | 9.87M | 13.1M | 9.88M | 14.5M | 79.0M | 123M | 44.4M | 6.77M | 4.35M | 2.98M |
| Gross Profit | 10.1M | 1.95M | 4.78M | 2.62M | 4.61M | 32.8M | 70.7M | 16.2M | -150K | 1.38M | 786K |
| Operating Income | -2.66M | -3.99M | -1.63M | -3.24M | -3.97M | 9.80M | 23.6M | -21.6M | -38.6M | -18.0M | -10.5M |
| EBITDA | -3.37M | -3.68M | -1.25M | -2.71M | -1.56M | 10.0M | 28.7M | -14.8M | -32.3M | -11.4M | -8.10M |
| Net Income | -2.87M | 41.8M | -1.74M | -3.15M | -2.13M | 6.27M | 18.5M | -16.8M | -53.4M | -14.7M | -16.8M |
| EPS | -1.68 | 27 | -1.53 | -2.72 | -1.83 | 3.41 | 9.90 | -9.75 | -28 | -1.74 | -1.20 |
| Balance Sheet | |||||||||||
| Total Assets | 12.8M | 34.2M | 20.7M | 12.3M | 31.4M | 89.3M | 87.6M | 91.9M | 63.2M | 59.9M | 57.4M |
| Total Liabilities | 6.84M | 1.07M | 4.23M | 1.04M | 20.8M | 30.7M | 24.0M | 42.5M | 55.8M | 56.4M | 60.5M |
| Shareholders' Equity | 5.96M | 31.8M | 16.5M | 11.2M | 10.6M | 58.6M | 63.6M | 49.4M | 7.35M | 3.51M | -3.11M |
| Cash & Short-term Investments | 441K | 21.9M | 8.24M | 1.36M | 8.46M | 17.5M | 17.4M | 4.74M | 678K | 90.0K | 20.0K |
| Total Debt | 1.49M | - | - | 926K | 14.7M | 14.9M | 6.96M | 18.5M | 24.6M | 8.62M | 9.12M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -472K | -2.84M | -2.12M | -841K | -2.59M | -13.6M | 28.6M | -11.3M | -17.5M | -8.34M | -1.65M |
| Capital Expenditure | 651K | 208K | 140K | 228K | 1.69M | 4.23M | 3.92M | 3.16M | 906K | 0.00 | 156K |
| Free Cash Flow | -1.12M | -3.05M | -2.26M | -1.07M | -4.28M | -17.9M | 24.6M | -14.5M | -18.4M | -8.34M | -1.65M |
| Ratios | |||||||||||
| ROE | -48.1% | 131.3% | -10.5% | -28.0% | -20.1% | 10.7% | 29.0% | -34.0% | -725.7% | -420.3% | - |
| ROA | -22.4% | 122.5% | -8.4% | -25.6% | -6.8% | 7.0% | 21.1% | -18.3% | -84.4% | -24.6% | -29.3% |
| Net Profit Margin | -13.6% | 423.9% | -13.3% | -31.9% | -14.6% | 7.9% | 15.1% | -37.8% | -788.2% | -339.3% | -564.5% |
| Debt to Equity | 0.25x | - | - | 0.08x | 1.39x | 0.25x | 0.11x | 0.37x | 3.34x | 2.46x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
ProPhase Labs Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- May 24, 2022
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 193K | 0.11 | - |
| 2022 | USD 9.35M | 5.01 | 50.7% |
| 2021 | USD 4.55M | 2.47 | 72.5% |
| 2020 | USD 2.89M | 2.50 | - |
| 2019 | USD 5.82M | 5.03 | - |
| 2018 | USD 11.7M | 10 | - |
| 2017 | USD 1.51M | 0.96 | 3.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on Dec 22, 2025.
Who owns ProPhase Labs Inc
- Insiders 7.61%
- Institutions 0.03%
- Public & others 92.36%
- Shares outstanding 15.6M
- Free float 15.3M
Top funds holding PRPH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Belfund SICAV Belinvest Equity A USD Acc | 5.00K | 0.03% | 0.00% | Jul 2026 |
| State St US Ttl Mkt Idx NL Cl A | 1.00 | 0.00% | 0.00% | Feb 2026 |
Top institutions holding PRPH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| CoreCap Advisors, LLC | 10.00 | 0.00% | 0.00% | Jun 2026 |
| BlackRock Inc | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Jane Street Group LLC | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Wells Fargo & Co | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Tower Research Capital LLC | 0.00 | 0.00% | -100.00% | Mar 2026 |
| HighTower Advisors, LLC | 0.00 | 0.00% | -100.00% | Mar 2026 |
| SIMPLEX TRADING, LLC | 0.00 | 0.00% | -100.00% | Mar 2026 |
| UBS Group AG | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Morgan Stanley - Brokerage Accounts | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Geode Capital Management, LLC | 0.00 | 0.00% | -100.00% | Mar 2026 |
| StoneX Group Inc | 0.00 | 0.00% | -100.00% | Mar 2026 |
| JPMorgan Chase & Co | 0.00 | 0.00% | -100.00% | Mar 2026 |
| SBI Securities Co Ltd | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Bank of America Corp | 0.00 | 0.00% | -100.00% | Mar 2026 |
ProPhase Labs Inc company profile
- Company name
- ProPhase Labs Inc
- Ticker
- PRPH.US
- Exchange
- USA Stocks
- Listed since
- Jan 16, 1997
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 19
- Fiscal year end
- December
- Address
- 626 RXR Plaz, Uniondale, NY, United States, 11556
- Phone
- 516 989 0763
- Website
- prophaselabs.com
About ProPhase Labs Inc
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides Nebula focuses on genomics testing technologies a comprehensive method for analyzing entire genomes, including the genes and chromosomes in deoxyribonucleic acid (DNA). It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Uniondale, New York.
ProPhase Labs Inc management
3- Mr. Ted William KarkusChairman & CEO · born 1959
- Mr. Jason KarkusPresident of Nebula Genomics
- Mr. Kevin QuinnChief Product Officer of Nebula Genomics